HLH Register |
RS |
Registrierung klinischer Daten und Laborparameter bei hämophagozytischer Lymphohistiozytose (HLH) |
ITP-Register |
RS |
ITP-Register und begleitende Bioproben-Sammlung |
CVAY736I12301 |
Phase III |
A Phase III. randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAYHIT1) |
CVAY736Q12301 |
Phase III |
A Phase III. randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response or relapsed after first line steroid treatment (VAYHIT2) |
CVAY736Q12201 |
Phase II |
A phase 2 study to evaluate the efficacy and safety of ianalumab (VAY736) in patients with primary immune thrombocytopenia (ITP) previously treated with at least a corticosteroid and a thrombopoietin receptor antagonist (TPO-RA) (VAYHIT3) |